Belkin Announces All-New Accessories for Apple Vision Pro at Web Summit 2024
Belkin, a leading consumer electronics brand for 40 years, today announced two new additions to its Apple Vision Pro accessories ecosystem — providing users with new ways to experience the revolutionary device. Belkin’s Apple Vision Pro accessories include the Battery Holder released earlier this year, and today the collection adds Travel Bag and Head Strap. The portfolio is now available to order at belkin.com, apple.com and select Apple Store locations worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241111678245/en/
Belkin announces Head Strap and Travel Bag for Apple Vision Pro at Web Summit 2024 (Photo: Business Wire)
“Since 1983, Belkin has been at the forefront of innovation, shaping the accessories ecosystem with every leap in hero devices. From pioneering the original cable that connected the Apple IIc to a parallel printer, we've been driving progress—leading the way and pushing boundaries wherever technology evolves," said Steve Malony, CEO, Belkin. “Fast forward to today, where Apple Vision Pro is transforming the way people interact with content. We are continuing to revolutionize the accessories ecosystem to multiply and amplify the ways that consumers and businesses use this powerful spatial computer.”
Head Strap for Apple Vision Pro
The Head Strap enhances comfort and stability for Apple Vision Pro users with its ergonomic and adjustable design. It is thoughtfully engineered with reinforced seams, a secure locking mechanism, and additional stabilization points to keep Vision Pro firmly in place on the user with weight evenly distributed. The easily adjustable strap ensures a precise fit for a wide range of head sizes.
Travel Bag for Apple Vision Pro
The Travel Bag is designed to protect Apple Vision Pro when taking it on-the-go. It is compact and lightweight and can be carried using the handle, or with the adjustable straps in either shoulder or cross-body style. The multi-compartment design keeps Vision Pro and accessories, such as the battery, power adapter and head bands — all organized and easily accessible. It is engineered with an internal flap and cushioned base for additional protection. The deep front zipper makes access easy, and additional pockets allow for extra storage for personal items. The Travel Bag is made with lightweight, high-performance fabric for durability, and comes in a timeless space gray color option.
These two products join Belkin’s Battery Holder for Apple Vision Pro. Designed to keep the battery’s position secure, the Battery Holder allows for a convenient and versatile hands-free experience.
Pricing and Availability
The Head Strap is available to order now for $49.95 USD on belkin.com, apple.com and select Apple Store locations in the US, China, Hong Kong, Japan, Singapore, Australia, Canada, France, Germany, and the UK.
The Travel Bag is available to order now for $99.95 USD on belkin.com, apple.com and select Apple Store locations in the US, China, Hong Kong, Japan, Singapore, Australia, Canada, France, Germany, and the UK.
The Battery Holder is available to order now for $49.95 USD on belkin.com, apple.com and select Apple Store locations in the US, China, Hong Kong, Japan, Singapore, Australia, Canada, France, Germany, and the UK.
Media kit available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241111678245/en/
Contacts
Media Contact
Jen Wei
VP Global Communications and Corporate Development
comms@belkin.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom